ZENNURE TAKCI, ÖZLEM TEKİN, Derun Taner ERTUĞRUL, Ayşe Serap KARADAĞ, Kadir Okhan AKIN

A case-control study: evaluation of vitamin D metabolism in patients with vitiligo

Background/aim: Reduced vitamin D is considered as one of the environmental factors that can increase the prevalence of certain autoimmune diseases. This study aimed to assess vitamin D metabolism in patients with vitiligo. Materials and methods: A prospective case-control study was conducted on 44 consecutive patients with vitiligo vulgaris and 43 healthy controls. Their plasma 25-hydroxyvitamin D (25(OH)D), parathormone (PTH), calcium, magnesium, and phosphate levels were measured. Results: There was no significant difference in the mean age, sex and Fitzpatrick skin phototype between the patient and control groups (P > 0.05). The plasma levels of 25(OH)D and calcium were signi?cantly decreased (P = 0.002, P < 0.0001, respectively) and PTH and magnesium levels were significantly increased in patients with vitiligo (P < 0.0001, P < 0.0001, respectively). The advancement of age (P = 0.03, R = -0.18) and comorbid autoimmune illnesses (P = 0.04) were found to be significantly associated with lower 25(OH)D levels. Conclusion: There is a universal lack of 25(OH)D in the Turkish population. Screening for vitamin D may be a tool for the presence of comorbid autoimmune diseases. Further studies are needed to understand the role of vitamin D metabolism in the pathogenesis of vitiligo.

Anahtar Kelimeler:

Vitiligo, 25-hydroxyvitamin D, vitamin D metabolism

A case-control study: evaluation of vitamin D metabolism in patients with vitiligo

Keywords:

Vitiligo, 25-hydroxyvitamin D, vitamin D metabolism,

PDF

___

Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167–181.
Le Poole IC, Wañkowicz-Kaliñska A, van den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9: 68–72.
Van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol 2014; 28: 741–746.
Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004; 229: 1136–1142.
Silverberg JI, Silverberg AI, Malka E, Silverberg N. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010; 62: 937–941.
Kriegel MA, Manson JE, Costenbader KH. Does vitamin D affect risk of developing autoimmune disease?: a systematic review. Semin Arthritis Rheum 2011; 40: 512–531.
Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685–698.
Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678–1688.
Aranow C. Vitamin D and the immune system. J Investig Med 2011; 59: 881–886.
Van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93–101.
Amano H, Abe M, Ishikawa O. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 2008; 25: 262–264.
Parsad D, Kanwar AJ. Topical vitamin D analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009; 22: 487–488.
Hann SK, Nordlund JJ. Clinical features of generalized vitiligo. In: Hann SK, Nordlund JJ, editors. Vitiligo. 1st ed. London, UK: Blackwell Science; 2000. pp. 35–36.
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–281.
Hekimsoy Z, Dinç G, Kafesçiler S, Onur E, Güvenç Y, Pala T, Güçlü F, Özmen B. Vitamin D status among adults in the Aegean region of Turkey. BMC Public Health 2010; 10: 782.
Van der Meer IM, Middelkoop BJ, Boeke AJ, Lips P. Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and Sub-Sahara African populations in Europe and their countries of origin: overview. Osteoporos Int 2011; 22: 1009–1021.
Aydıngöz IE, Bingül I, Doğru-Abbasoğlu S, Vural P, Uysal M. Analysis of vitamin d receptor gene polymorphisms in vitiligo. Dermatology 2012; 224: 361–368.
Li K, Shi Q, Yang L, Li X, Liu L, Wang L, Li Q, Wang G, Li CY, Gao TW. The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol 2012; 167: 815–821.
Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmunol Photomed 2013; 29: 34–40.
Xu X, Fu WW, Wu WY. Serum 25-hydroxyvitamin D deficiency in Chinese patients with vitiligo: a case-control study. PLoS One 2012; 7: e52778.
Zofková I, Kancheva RL. The relationship between magnesium and calciotropic hormones. Magnes Res 1995; 8: 77–84.
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90–100.
Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579–2585.
Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 2003; 49: 277–300.
Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137–1142.
Penna G, Adorini L. 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411.
Berer A, Stöckl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L. 1,25-Dihydroxyvitamin D3 inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 2000; 28: 575–583.
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008; 9: 345–359.
Watabe H, Soma Y, Kawa Y, Ito M, Ooka S, Ohsumi K, Baba T, Kawakami T, Hosaka E, Kimura S et al. Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 2002; 119: 583–589.
Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E, Zeher M, Szegedi G, Bodolay E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 2008; 10: R123.
Munger KL, Zhang SM, O’Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60–65.
Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93: 512–517.
Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007; 7: 59–64.